Home / Shop / Synedica Retatrutide 40mg Injection Kit
Synedica Retatrutide 40mg Injection Kit
The Retatrutide 40mg Injection Kit supplies retatrutide (LY3437943, CAS 2381089-83-2), a 39-amino-acid triple agonist peptide activating GLP-1, GIP and glucagon receptors, studied in Phase 2 and Phase 3 clinical trials for metabolic and liver research. Synedica UK offers this kit for sale strictly for laboratory and in-vitro research use, not as a licensed medicine.
£130.00 – £32000.00
Kits
Size
Form: Injection Kit
Quantity
Form: Injection Kit
Pack Size: 40mg
Storage & Handling
Storage (Lyophilized): Store at -20°C in a dry, desiccated environment. – After Reconstitution: Store reconstituted peptide at 2–8°C and use within 30 days. For long-term storage, aliquot and freeze at -20°C. Avoid repeated freeze-thaw cycles. – Reconstitution: Reconstitute in sterile bacteriostatic water or appropriate buffer depending on experimental needs.
â ï¸ This product is sold strictly for in vitro research and laboratory use only. It is not for human or veterinary use. By purchasing or using this product, the buyer agrees they have read, understood and accept the Terms & Conditions of Synedica UK. Terms & Conditions.
Retatrutide's Phase 3 headlines have pulled a lot of new attention toward the compound, and with attention comes an uptick in mislabelled vials and inflated purity claims. Researchers who've been sourcing peptides for a while know the routine: check the batch number, check the testing method, and don't assume a trial result printed in a major journal means every vial on the market matches the label. This page sets out what the Retatrutide 40mg Injection Kit is, what current clinical research has actually found, and how to verify what you're buying before it goes anywhere near the bench.
What Retatrutide Is
Retatrutide (development code LY3437943) is a single-molecule, 39-amino-acid peptide and the first triple hormone-receptor agonist in its class, designed to simultaneously activate the glucagon-like peptide-1 (GLP-1) receptor, the glucose-dependent insulinotropic polypeptide (GIP) receptor, and the glucagon receptor. It carries CAS number 2381089-83-2, molecular formula C221H342N46O68, and a molecular weight of approximately 4,731.4 g/mol. Combining three receptor targets in one molecule distinguishes it from single-target GLP-1 agonists and dual GIP/GLP-1 agonists studied earlier in the same drug class.
What Current Research Says
Retatrutide's Phase 2 obesity trial, led by Jastreboff and colleagues, was published in the New England Journal of Medicine on 26 June 2023. Over 48 weeks, participants receiving the highest studied dose (12 mg weekly) recorded a mean body-weight reduction of 24.2%, compared with 2.1% on placebo, with the weight-loss curve not yet plateaued at the study's end (Jastreboff et al., 2023, N Engl J Med).
A separate Phase 2a substudy examining metabolic dysfunction-associated steatotic liver disease (MASLD), published in Nature Medicine on 10 June 2024, reported mean relative liver-fat reductions of up to 82.4% at the 12 mg dose after 24 weeks, with 86% of participants on that dose reaching normal liver-fat levels compared with 0% on placebo (Sanyal et al., 2024, Nat Med).
Phase 3 data have since extended the picture. The Pharmaceutical Journal reported on 22 May 2026 that the TRIUMPH-1 trial recorded a 25.0% average body-weight reduction at 80 weeks on the 12 mg dose, rising to as much as 30% at 104 weeks among participants with severe obesity who escalated to their maximum tolerated dose. Lead investigator Ania Jastreboff was quoted noting “clear improvements in assessed cardiometabolic health measures” alongside the weight changes (The Pharmaceutical Journal, 22 May 2026).
A further Phase 3 trial, TRIUMPH-4, examined retatrutide alongside knee osteoarthritis outcomes. Results announced on 11 December 2025 reported WOMAC pain-subscale reductions of 74–76% on active treatment versus 40% on placebo, alongside body-weight reductions of up to 28.7% at the 12 mg dose (Eli Lilly and Company, 11 December 2025). None of these findings constitute a treatment claim for this research-use product; they describe what has been studied in registered clinical trials of the molecule, not what any laboratory-use compound sold by Synedica UK does for an individual.
Retatrutide vs Related Research Peptides
Retatrutide 40mg Injection Kit is one of several incretin-pathway peptides studied in metabolic research; the table below summarises how its chemical identity compares with two related compounds also supplied by Synedica UK for laboratory use.
| Property | Retatrutide | Tirzepatide | Semaglutide |
|---|---|---|---|
| Receptor targets | GLP-1, GIP, glucagon (triple) | GIP, GLP-1 (dual) | GLP-1 (single) |
| CAS number | 2381089-83-2 | 2023788-19-2 | 910463-68-2 |
| Molecular formula | C221H342N46O68 | C225H348N48O68 | C187H291N45O59 |
| Molecular weight | ≈4,731.4 g/mol | ≈4,813.5 g/mol | ≈4,113.6 g/mol |
| Amino acid count | 39 | 39 | 31 |
Batch-specific purity, storage conditions and testing method are confirmed on each product's Certificate of Analysis rather than assumed from the class average — see the purity section below. The Synedica Tirzepatide 40mg Injection Pen Kit and Synedica Semaglutide GLP-1 Pen Kit pages carry their own batch documentation.
Purity and Certificate of Analysis Standards
Every Retatrutide 40mg Injection Kit offered for sale is supplied with third-party analytical documentation rather than a single purity percentage repeated across listings. A Certificate of Analysis (COA) should show the specific batch or lot number, the analytical method used (typically HPLC or mass spectrometry), the measured purity result for that batch, and the issuing laboratory. Given how much retatrutide is currently being sold under widely varying purity claims, researchers should treat a listing without batch-specific COA access as a red flag rather than an oversight.
Sourcing and Verification
Buying a high-demand compound like retatrutide from a UK-based supplier does not remove the need to verify what arrives. Before ordering, check that the listing states research-use status clearly, that batch documentation is offered rather than promised only “on request,” and that the compound identity (CAS number, molecular formula) is independently verifiable against a source such as PubChem. The Retatrutide 40mg Injection Kit is offered for sale on this basis, with documentation available per batch rather than as a one-off marketing claim.
Frequently Asked Questions
What is the Retatrutide 40mg Injection Kit used for?
It supplies retatrutide, a triple GLP-1/GIP/glucagon receptor agonist peptide, for laboratory and in-vitro research into incretin-receptor pharmacology and metabolic signalling pathways. It is not sold for any therapeutic, dietary, or performance use.
Is it legal to buy retatrutide as a research chemical in the UK?
UK researchers and laboratories can lawfully purchase compounds such as retatrutide when they are supplied and marketed strictly for research or in-vitro use rather than as a medicine. This product is not licensed under the Human Medicines Regulations 2012 (SI 2012/1916) and has not been assessed by the MHRA for human safety or efficacy, so it must not be purchased for human or veterinary use.
What does the Certificate of Analysis (COA) show?
A COA should confirm the batch number, the analytical testing method (typically HPLC or mass spectrometry), the measured purity for that specific batch, and the issuing laboratory, allowing a researcher to verify what a given batch actually contains rather than relying on a generic listing description.
How is the CAS number used to verify this compound?
CAS 2381089-83-2 identifies retatrutide specifically. Researchers can cross-check this number, the molecular formula (C221H342N46O68), and the molecular weight (approximately 4,731.4 g/mol) against an independent database such as PubChem to confirm chemical identity before use.
How does retatrutide differ from tirzepatide and semaglutide?
Retatrutide activates three receptors — GLP-1, GIP and glucagon — while tirzepatide activates two (GIP and GLP-1) and semaglutide activates one (GLP-1 only). All three are peptides studied in incretin-pathway research, but they are distinct molecules with different CAS numbers, molecular weights, and receptor-binding profiles; see the comparison table above.
What has clinical research found about retatrutide so far?
Registered Phase 2 and Phase 3 trials, published in journals including the New England Journal of Medicine and Nature Medicine, have examined retatrutide's effects on body weight, liver fat, and osteoarthritis-related pain in study populations. These findings describe outcomes recorded in formal clinical trials of the molecule; they are not claims about this research-use product, which is not licensed as a medicine.
Does the product form (injection kit) affect the research application?
The kit format is a delivery/packaging format only. This listing makes no dosing, administration, or reconstitution recommendations; researchers determine their own protocols in line with their institution's research and safety governance.
How should the Retatrutide 40mg Injection Kit be stored before use?
Store according to the conditions printed on the batch documentation and product label, generally in cool, dry, dark conditions. Exact storage parameters and shelf life are batch-specific and confirmed on the accompanying documentation.
How does this differ from an MHRA-licensed medicine containing similar targets?
An MHRA-licensed medicine has been formally assessed for safety, quality and efficacy for a specific human therapeutic use and carries a marketing authorisation. Retatrutide has not completed that assessment process in the UK, carries no marketing authorisation here, and this product is supplied strictly for laboratory and in-vitro research — it is not an alternative to any licensed medicine.
Can this product be used in human or veterinary applications?
No. It is sold strictly for laboratory and in-vitro research use. It is not a medicine, is not for human or veterinary use or consumption, is not licensed under the Human Medicines Regulations 2012, and has not been assessed by the MHRA for safety or efficacy.
Does Synedica UK ship the Retatrutide 40mg Injection Kit within the UK?
Yes, this product is offered for UK delivery to research buyers.
Where can I buy the Retatrutide 40mg Injection Kit for research use?
It is available for sale directly from Synedica UK, supplied with batch documentation and third-party testing for verified UK research buyers.
Related Reading
Author: Synedica UK Science & QA Team
Last updated: 29 August 2026